We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+49.66%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$813M
AUM Growth
+$268M
Cap. Flow
+$77.2M
Cap. Flow %
9.49%
Top 10 Hldgs %
63.05%
Holding
46
New
14
Increased
4
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$24.9M
2
ASND icon
Ascendis Pharma A/S
ASND
+$23.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$19.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$18M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$18M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$29.2M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$27.9M
3
VTYX
Ventyx Biosciences
VTYX
+$20.3M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$14.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
26
DELISTED
Kezar Life Sciences
KZR
$8.18M 1.01%
95,000
– –
CMPS
27
Compass Pathways
CMPS
$1.52B
$5.47M 0.67%
+510,000
New +$7.64M
GERN icon
28
Geron
GERN
$949M
$4.68M 0.58%
+2,000,000
New +$4.48M
IPSC icon
29
Century Therapeutics
IPSC
$381M
$4.55M 0.56%
460,075
-16,484
-3% -$174K
TCDA
30
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.52M 0.31%
+240,200
New +$2.63M
VIGL
31
DELISTED
Vigil Neuroscience
VIGL
$1.87M 0.23%
205,595
– –
CNTA
32
DELISTED
Centessa Pharmaceuticals
CNTA
$1.61M 0.2%
399,801
– –
TIL icon
33
Instil Bio
TIL
$48.6M
$1.61M 0.2%
16,594
-1,896
-10% -$217K
SPRB
34
Spruce Biosciences
SPRB
$121M
$1.37M 0.17%
13,333
– –
TYRA icon
35
Tyra Biosciences
TYRA
$1.88B
$1.12M 0.14%
127,316
-39,210
-24% -$359K
LIAN
36
DELISTED
LianBio American Depositary Shares
LIAN
$616K 0.08%
307,908
-86,578
-22% -$207K
TRML
37
DELISTED
Tourmaline Bio
TRML
$521K 0.06%
19,791
-7,308
-27% -$266K
PYXS icon
38
Pyxis Oncology
PYXS
$183M
$434K 0.05%
220,434
– –
NUVB.WS
39
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13K ﹤0.01%
66,666
– –
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$4.35B
– –
-650,000
Closed -$9.16M
LONA
41
LeonaBio Inc
LONA
$67.6M
– –
-22,000
Closed -$671K
EWTX icon
42
Edgewise Therapeutics
EWTX
$4.43B
– –
-150,000
Closed -$1.19M
NBIX icon
43
Neurocrine Biosciences
NBIX
$17.7B
– –
-300,000
Closed -$29.2M
NUVL
44
DELISTED
Nuvalent
NUVL
– –
-33,887
Closed -$460K
CCXI
45
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-600,000
Closed -$14.9M
HZNP
46
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-350,000
Closed -$27.9M
1
2

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2022 Portfolio in Review

As of Q3 2022, Logos Global Management held 46 positions worth $813M, up 49% from $545M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Logos Global Management deployed $77.2M of net new capital in Q3 2022, opening 14 new positions and adding to 4 existing holdings. Its largest new stake was Allakos: 5,936,666 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Ventyx Biosciences, an estimated $20.3M trimmed.

  • Logos Global Management's largest Q3 2022 buy was Allakos: 5,936,666 shares worth $36.3M.
  • Logos Global Management added most to Arcutis Biotherapeutics in Q3 2022, an estimated $11.9M increase.
  • Logos Global Management's biggest Q3 2022 reduction was Ventyx Biosciences, cutting an estimated $20.3M.
  • Logos Global Management fully exited Neurocrine Biosciences in Q3 2022, selling an estimated $29.2M.
  • Logos Global Management's ten largest holdings make up 63% of its $813M portfolio in Q3 2022.
  • Logos Global Management opened 14 new positions and closed 7 in Q3 2022.
  • Logos Global Management's portfolio value rose 49% quarter-over-quarter to $813M.

Based on Logos Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.